{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:29Z","timestamp":1793410769807,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary diseases are important causes of morbidity globally. Atorvastatin's pleiotropic effects, which include anti-inflammatory and lipid-lowering properties, may be beneficial for individuals with respiratory diseases. This meta-analysis evaluated the atorvastatin's effect on inflammatory biomarkers, lipid profile, liver enzymes, and pulmonary function in lung disease patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed\/MEDLINE, Scopus, Web of Science, Embase, CENTRAL, and Google Scholar for English-language RCTs until March 2025. The study evaluated inflammatory markers (CRP, IL-6, TNF-\u03b1), lipid profile (LDL, HDL, TC, TG), liver enzymes (ALT, AST), pulmonary function tests, and physical performance. Pooled weighted mean differences (WMDs) with 95% confidence intervals were calculated using random-effects models. Subgroup, heterogeneity, and publication bias analyses were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventeen RCTs (22 datasets;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,344) on asthma, COPD, COVID-19, pulmonary hypertension, and associated disorders were analyzed. Atorvastatin substantially decreased TNF-\u03b1 (WMD: \u2212\u00a00.20\u00a0pg\/mL; 95% CI \u2212\u00a00.28 to \u2212\u00a00.11), LDL cholesterol (WMD: \u2212\u00a021.48\u00a0mg\/dL; 95% CI \u2212\u00a030.82 to \u2212\u00a012.14), and TC (WMD: \u2212\u00a015.24\u00a0mg\/dL; 95% CI \u2212\u00a028.28 to \u2212\u00a02.20), while improving 6MWD (WMD: 0.71; 95% CI 0.24 to 1.17) and FEF25-75 in COPD subgroups. Evening peak expiratory flow (PEF) was considerably lower (WMD: \u2212\u00a08.72; 95% CI \u2212\u00a014.96 to \u2212\u00a02.47), indicating worsening in airway airflow throughout the evening. There were no significant overall effects for CRP, IL-6, triglycerides, HDL, FEV1, FVC, or oxygen saturation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Atorvastatin demonstrates anti-inflammatory and lipid-lowering efficacy in pulmonary disease patients, with mild functional respiratory benefits and modest improvements in physical performance. Additional large-scale studies are needed to validate clinical benefits and effective treatment methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03782-y","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:35:05Z","timestamp":1768829705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of atorvastatin on inflammatory\nmarkers, lipid profile, liver enzymes,\nand pulmonary function in patients with lung\ndiseases: a systematic review\nand meta-analysis of randomized\ncontrolled trials"],"prefix":"10.1186","volume":"31","author":[{"given":"Samane","family":"Baseri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Mahdieh","family":"Khoshnazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nikdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiavash","family":"Hushmandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"3","key":"3782_CR1","first-page":"167","volume":"4","author":"DH Walker","year":"1995","unstructured":"Walker DH, Dumler JS. Will pathologists play as important a role in the future as they have in the past against the challenge of infectious diseases. Infect Agent Dis. 1995;4(3):167\u201370.","journal-title":"Infect Agent Dis"},{"issue":"49","key":"3782_CR2","doi-asserted-by":"publisher","first-page":"12501","DOI":"10.1073\/pnas.1811787115","volume":"115","author":"B Button","year":"2018","unstructured":"Button B, et al. Roles of mucus adhesion and cohesion in cough clearance. Proc Natl Acad Sci U S A. 2018;115(49):12501\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3782_CR3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3782_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/15412555.2021.1963695","volume":"18","author":"B Thomas","year":"2021","unstructured":"Thomas B, et al. Dysfunctional bronchial cilia are a feature of chronic obstructive pulmonary disease (COPD). COPD. 2021;18(6):657\u201363.","journal-title":"COPD"},{"issue":"12","key":"3782_CR5","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.rmed.2006.03.012","volume":"100","author":"PT King","year":"2006","unstructured":"King PT, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100(12):2183\u20139.","journal-title":"Respir Med"},{"issue":"4","key":"3782_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4065\/mcp.2010.0820","volume":"86","author":"IG Sia","year":"2011","unstructured":"Sia IG, Wieland ML. Current concepts in the management of tuberculosis. Mayo Clin Proc. 2011;86(4):348\u201361.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"3782_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2214\/ajr.160.4.8456658","volume":"160","author":"KS Lee","year":"1993","unstructured":"Lee KS, et al. Adult-onset pulmonary tuberculosis: findings on chest radiographs and CT scans. AJR Am J Roentgenol. 1993;160(4):753\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"3782_CR8","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3782_CR9","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3782_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"3782_CR11","unstructured":"COVID-19 Coronavirus Pandemic. 2024. https:\/\/www.worldometers.info\/coronavirus\/."},{"issue":"6","key":"3782_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","volume":"75","author":"K Saku","year":"2011","unstructured":"Saku K, et al. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL)\u2013the PATROL trial\u2013. Circ J. 2011;75(6):1493\u2013505.","journal-title":"Circ J"},{"issue":"5","key":"3782_CR13","first-page":"404","volume":"29","author":"WC Huang","year":"2013","unstructured":"Huang WC, et al. The effect of intensified low density lipoprotein cholesterol reduction on recurrent myocardial infarction and cardiovascular mortality. Acta Cardiol Sin. 2013;29(5):404\u201312.","journal-title":"Acta Cardiol Sin"},{"issue":"8","key":"3782_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/M14-1430","volume":"162","author":"MC Odden","year":"2015","unstructured":"Odden MC, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med. 2015;162(8):533\u201341.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3782_CR15","first-page":"Cd004816","volume":"2013","author":"F Taylor","year":"2013","unstructured":"Taylor F, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):Cd004816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"3782_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1161\/01.ATV.0000022694.16328.CC","volume":"22","author":"A Rezaie-Majd","year":"2002","unstructured":"Rezaie-Majd A, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22(7):1194\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9157","key":"3782_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","volume":"353","author":"RS Rosenson","year":"1999","unstructured":"Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353(9157):983\u20134.","journal-title":"Lancet"},{"key":"3782_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89\u2013118.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"3782_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen SE, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"3782_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117\u201325.","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"3782_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3892\/etm.2017.4576","volume":"14","author":"MW Liu","year":"2017","unstructured":"Liu MW, et al. Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression. Exp Ther Med. 2017;14(2):917\u201330.","journal-title":"Exp Ther Med"},{"key":"3782_CR22","unstructured":"Hothersall EJ. Effect of atorvastatin on asthma control and airway inflammation: a randomised controlled trial. 2008."},{"key":"3782_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100875","author":"L Davoodi","year":"2021","unstructured":"Davoodi L, et al. Atorvastatin therapy in COVID-19 adult inpatients: a double-blind, randomized controlled trial. IJC Heart Vasc. 2021. https:\/\/doi.org\/10.1016\/j.ijcha.2021.100875.","journal-title":"IJC Heart Vasc"},{"issue":"12","key":"3782_CR24","doi-asserted-by":"publisher","first-page":"300060521106372","DOI":"10.1177\/03000605211063721","volume":"49","author":"S Mehrabi","year":"2021","unstructured":"Mehrabi S, Torkan J, Hosseinzadeh M. Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial. J Int Med Res. 2021;49(12):3000605211063721.","journal-title":"J Int Med Res"},{"key":"3782_CR25","unstructured":"Hothersall EJ, Effect of atorvastatin on asthma control and airway inflammation: a randomised controlled trial. University of Glasgow. 2008."},{"issue":"1","key":"3782_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12879-022-07570-5","volume":"22","author":"N Ghati","year":"2022","unstructured":"Ghati N, et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial). BMC Infect Dis. 2022;22(1):606.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"3782_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12890-021-01481-y","volume":"21","author":"B Momeni","year":"2021","unstructured":"Momeni B, et al. The effect of atorvastatin on inflammatory markers in sulfur mustard gas induced bronchitis: a randomized double-blinded, placebo-control clinical trial. BMC Pulm Med. 2021;21(1):112.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"3782_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4168\/aair.2012.4.5.290","volume":"4","author":"A Moini","year":"2012","unstructured":"Moini A, Azimi G, Farivar A. Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy, Asthma Immunol Res. 2012;4(5):290\u20134.","journal-title":"Allergy, Asthma Immunol Res"},{"issue":"2","key":"3782_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/amhs.amhs_124_16","volume":"5","author":"M Bisht","year":"2017","unstructured":"Bisht M, Rawat J. Effect of atorvastatin on high sensitivity C-reactive protein, pulmonary function, and quality of life in chronic obstructive pulmonary disease - an open-labeled randomized control trial. Arch Med Health Sci. 2017;5(2):167\u201371.","journal-title":"Arch Med Health Sci"},{"issue":"2","key":"3782_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/ejb.ejb_50_17","volume":"13","author":"YM Mohamed","year":"2019","unstructured":"Mohamed YM, et al. The impact of adjuvant atorvastatin therapy on community-acquired pneumonia outcome: a prospective study of clinical and inflammatory responses in relation to mortality reduction. Egypt J Bronchol. 2019;13(2):249\u201357.","journal-title":"Egypt J Bronchol"},{"issue":"12","key":"3782_CR31","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/thx.2008.100198","volume":"63","author":"EJ Hothersall","year":"2008","unstructured":"Hothersall EJ, et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax. 2008;63(12):1070\u20135.","journal-title":"Thorax"},{"issue":"3","key":"3782_CR32","first-page":"969","volume":"11","author":"MM Mohammad","year":"2012","unstructured":"Mohammad MM, et al. Methacoline Challenge test as an evaluator of response to statins in bronchial hyperresponsiveness. Iran J Pharm Res. 2012;11(3):969\u201377.","journal-title":"Iran J Pharm Res"},{"issue":"8","key":"3782_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.5812\/ircmj.8267","volume":"15","author":"SAJ Moosavi","year":"2013","unstructured":"Moosavi SAJ, et al. Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial. Iran Red Crescent Med J. 2013;15(8):649\u201354.","journal-title":"Iran Red Crescent Med J"},{"issue":"2","key":"3782_CR34","first-page":"99","volume":"19","author":"H Ghobadi","year":"2014","unstructured":"Ghobadi H, et al. The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: a randomized controlled trial. J Res Med Sci. 2014;19(2):99\u2013105.","journal-title":"J Res Med Sci"},{"issue":"1","key":"3782_CR35","first-page":"111","volume":"66","author":"RM Mroz","year":"2015","unstructured":"Mroz RM, et al. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease: a controlled pilot study. J Physiol Pharmacol. 2015;66(1):111\u201328.","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"3782_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1183\/09031936.00149011","volume":"40","author":"WJ Zeng","year":"2012","unstructured":"Zeng WJ, et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J. 2012;40(1):67\u201374.","journal-title":"Eur Respir J"},{"issue":"3","key":"3782_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/jrpp.JRPP_17_93","volume":"7","author":"A Arian","year":"2018","unstructured":"Arian A, et al. Trial of atorvastatin on serum interleukin-6, total antioxidant capacity, C-reactive protein, and alpha-1 antitrypsin in patients with chronic obstructive pulmonary disease. J Res Pharm Pract. 2018;7(3):141\u20136.","journal-title":"J Res Pharm Pract"},{"key":"3782_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/423120","volume":"2014","author":"M Joyeux-Faure","year":"2014","unstructured":"Joyeux-Faure M, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. Mediators Inflamm. 2014;2014:423120.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"3782_CR39","first-page":"334","volume":"23","author":"SG Mortazavi Moghadam","year":"2016","unstructured":"Mortazavi Moghadam SG, et al. Effect of Atorvastatin on blood and gasometrical parameters in patients with COPD: A double-blind controlled clinical trial. J Birjand Univ Med Sci. 2016;23(4):334\u201341.","journal-title":"J Birjand Univ Med Sci"},{"issue":"7650","key":"3782_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"3782_CR41","doi-asserted-by":"publisher","first-page":"30060","DOI":"10.1038\/srep30060","volume":"6","author":"M Rysz-G\u00f3rzynska","year":"2016","unstructured":"Rysz-G\u00f3rzynska M, et al. Efficacy of statin therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Sci Rep. 2016;6:30060.","journal-title":"Sci Rep"},{"issue":"8","key":"3782_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24334","volume":"47","author":"H Soleimani","year":"2024","unstructured":"Soleimani H, et al. Safety and effectiveness of high-intensity statins versus low\/moderate-intensity statins plus ezetimibe in patients with atherosclerotic cardiovascular disease for reaching LDL-C goals: a systematic review and meta-analysis. Clin Cardiol. 2024;47(8):e24334.","journal-title":"Clin Cardiol"},{"key":"3782_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100875","volume":"36","author":"L Davoodi","year":"2021","unstructured":"Davoodi L, et al. Atorvastatin therapy in COVID-19 adult inpatients: a double-blind, randomized controlled trial. IJC Heart Vasc. 2021;36:100875.","journal-title":"IJC Heart Vasc"},{"issue":"1","key":"3782_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.anai.2012.09.002","volume":"110","author":"CF Huang","year":"2013","unstructured":"Huang CF, et al. Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice. Ann Allergy Asthma Immunol. 2013;110(1):11\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3782_CR45","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/j.dsx.2020.10.021","volume":"14","author":"MM Minz","year":"2020","unstructured":"Minz MM, Bansal M, Kasliwal RR. Statins and SARS-CoV-2 disease: current concepts and possible benefits. Diabetes Metab Syndr. 2020;14(6):2063\u20137.","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"3782_CR46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4168\/aair.2012.4.5.290","volume":"4","author":"A Moini","year":"2012","unstructured":"Moini A, Azimi G, Farivar A. Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy Asthma Immunol Res. 2012;4(5):290\u20134.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"3782_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1465-9921-13-108","volume":"13","author":"C Yuan","year":"2012","unstructured":"Yuan C, et al. Statins as potential therapeutic drug for asthma? Respir Res. 2012;13(1):108.","journal-title":"Respir Res"},{"issue":"1","key":"3782_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.intimp.2013.05.016","volume":"17","author":"AC Melo","year":"2013","unstructured":"Melo AC, et al. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol. 2013;17(1):57\u201364.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3782_CR49","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bbrc.2014.02.091","volume":"446","author":"X Yuan","year":"2014","unstructured":"Yuan X, et al. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4\/MYD88 pathway. Biochem Biophys Res Commun. 2014;446(1):292\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"3782_CR50","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","volume":"5","author":"M Madjid","year":"2020","unstructured":"Madjid M, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831\u201340.","journal-title":"JAMA Cardiol"},{"key":"3782_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00398-20","author":"DS Fedson","year":"2020","unstructured":"Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. MBio. 2020. https:\/\/doi.org\/10.1128\/mBio.00398-20.","journal-title":"MBio"},{"issue":"5","key":"3782_CR52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1046\/j.1365-2036.2000.00723.x","volume":"14","author":"S Somasundaram","year":"2000","unstructured":"Somasundaram S, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther. 2000;14(5):639\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3782_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1084\/jem.20040566","volume":"200","author":"MJ Paul-Clark","year":"2004","unstructured":"Paul-Clark MJ, et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med. 2004;200(1):69\u201378.","journal-title":"J Exp Med"},{"issue":"7","key":"3782_CR54","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","volume":"9","author":"I Mazur","year":"2007","unstructured":"Mazur I, et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 2007;9(7):1683\u201394.","journal-title":"Cell Microbiol"},{"key":"3782_CR55","doi-asserted-by":"publisher","DOI":"10.4103\/amhs.amhs_124_16","author":"M Bisht","year":"2017","unstructured":"Bisht M, Rawat J. Effect of atorvastatin on high sensitivity C-reactive protein, pulmonary function, and quality of life in chronic obstructive pulmonary disease - an open-labeled randomized control trial. Arch Med Health Sci. 2017. https:\/\/doi.org\/10.4103\/amhs.amhs_124_16.","journal-title":"Arch Med Health Sci"},{"issue":"12","key":"3782_CR56","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.clinthera.2008.12.023","volume":"30","author":"J Bonnet","year":"2008","unstructured":"Bonnet J, et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008;30(12):2298\u2013313.","journal-title":"Clin Ther"},{"issue":"6","key":"3782_CR57","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects\u202f: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373\u2013418.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"3782_CR58","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/cid\/cis733","volume":"55","author":"EM Mortensen","year":"2012","unstructured":"Mortensen EM, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55(11):1466\u201373.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3782_CR59","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1473-3099(07)70111-1","volume":"7","author":"M Terblanche","year":"2007","unstructured":"Terblanche M, et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007;7(5):358\u201368.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3782_CR60","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.amjcard.2007.09.102","volume":"101","author":"TM Lee","year":"2008","unstructured":"Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530\u20135.","journal-title":"Am J Cardiol"},{"issue":"2","key":"3782_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1183\/09031936.00106406","volume":"29","author":"V S\u00f8yseth","year":"2007","unstructured":"S\u00f8yseth V, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279\u201383.","journal-title":"Eur Respir J"},{"issue":"5","key":"3782_CR62","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1183\/09031936.00093908","volume":"32","author":"RP Young","year":"2008","unstructured":"Young RP, et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J. 2008;32(5):1158\u201364.","journal-title":"Eur Respir J"},{"issue":"9","key":"3782_CR63","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1517\/17425247.2011.588697","volume":"8","author":"L Marin","year":"2011","unstructured":"Marin L, et al. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv. 2011;8(9):1205\u201320.","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"3782_CR64","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1164\/rccm.200501-041OC","volume":"172","author":"JH Lee","year":"2005","unstructured":"Lee JH, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005;172(8):987\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3782_CR65","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1183\/09031936.00042512","volume":"42","author":"BB Davis","year":"2013","unstructured":"Davis BB, et al. Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. Eur Respir J. 2013;42(2):350\u201361.","journal-title":"Eur Respir J"},{"key":"3782_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2015.01.001","volume":"31","author":"NC Thomson","year":"2015","unstructured":"Thomson NC, et al. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther. 2015;31:1\u20138.","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"3782_CR67","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","volume":"33","author":"A Endo","year":"1992","unstructured":"Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569\u201382.","journal-title":"J Lipid Res"},{"issue":"1","key":"3782_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154(1):69\u201375.","journal-title":"Immunology"},{"issue":"3","key":"3782_CR69","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bcp.2014.11.013","volume":"93","author":"K Tikoo","year":"2015","unstructured":"Tikoo K, et al. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol. 2015;93(3):343\u201351.","journal-title":"Biochem Pharmacol"},{"key":"3782_CR70","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61390","author":"N Zamorano Cuervo","year":"2020","unstructured":"Zamorano Cuervo N, Grandvaux N. ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.61390.","journal-title":"Elife"},{"issue":"4","key":"3782_CR71","first-page":"176","volume":"8","author":"F Dastan","year":"2020","unstructured":"Dastan F, Salamzadeh J, et al. Atorvastatin-Induced Myalgia in Iranian Patients: A Hospital-Based Study to Determine the Prevalence and Associated Risk Factors. J Pharm Care. 2020;8(4):176\u20139.","journal-title":"J Pharm Care"},{"issue":"114","key":"3782_CR72","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1183\/09059180.00005309","volume":"18","author":"RP Young","year":"2009","unstructured":"Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18(114):222\u201332.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"3782_CR73","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1378\/chest.08-2420","volume":"136","author":"A Chaouat","year":"2009","unstructured":"Chaouat A, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136(3):678\u201387.","journal-title":"Chest"},{"issue":"3","key":"3782_CR74","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1592\/phco.26.3.333","volume":"26","author":"I Zineh","year":"2006","unstructured":"Zineh I, et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy. 2006;26(3):333\u201340.","journal-title":"Pharmacotherapy"},{"issue":"1\u20134","key":"3782_CR75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/biof.5520180213","volume":"18","author":"S Passi","year":"2003","unstructured":"Passi S, et al. Statins lower plasma and lymphocyte ubiquinol\/ubiquinone without affecting other antioxidants and PUFA. BioFactors. 2003;18(1\u20134):113\u201324.","journal-title":"BioFactors"},{"issue":"6","key":"3782_CR76","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00210-006-0082-1","volume":"373","author":"P Guerard","year":"2006","unstructured":"Guerard P, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):401\u201314.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"3782_CR77","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1515\/aiht-2017-68-2994","volume":"68","author":"B Karahalil","year":"2017","unstructured":"Karahalil B, et al. Hepatotoxicity associated with statins. Arh Hig Rada Toksikol. 2017;68(4):254\u201360.","journal-title":"Arh Hig Rada Toksikol"},{"issue":"4","key":"3782_CR78","doi-asserted-by":"publisher","first-page":"98543","DOI":"10.5493\/wjem.v14.i4.98543","volume":"14","author":"ZI Tarar","year":"2024","unstructured":"Tarar ZI, et al. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. World J Exp Med. 2024;14(4):98543.","journal-title":"World J Exp Med"},{"issue":"1","key":"3782_CR79","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","volume":"70","author":"E Pose","year":"2019","unstructured":"Pose E, et al. Statins: old drugs as new therapy for liver diseases? J Hepatol. 2019;70(1):194\u2013202.","journal-title":"J Hepatol"},{"issue":"1","key":"3782_CR80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2466-11-16","volume":"11","author":"G Braganza","year":"2011","unstructured":"Braganza G, et al. Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial. BMC Pulm Med. 2011;11(1):16.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"3782_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4104\/pcrj.2011.00095","volume":"21","author":"CM Lawes","year":"2012","unstructured":"Lawes CM, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J. 2012;21(1):35\u201340.","journal-title":"Prim Care Respir J"},{"issue":"1","key":"3782_CR82","first-page":"13","volume":"5","author":"F Fanak","year":"2009","unstructured":"Fanak F, et al. Do statins improve lung function in asthmatic patients? A randomized and double-blind trial: role of statins in asthma. Iran J Pharm Sci. 2009;5(1):13\u201320.","journal-title":"Iran J Pharm Sci"},{"issue":"3","key":"3782_CR83","first-page":"969","volume":"11","author":"M Malek Mohammad","year":"2012","unstructured":"Malek Mohammad M, et al. Methacoline challenge test as an evaluator of response to statins in bronchial hyperresponsiveness. Iran J Pharm Res. 2012;11(3):969\u201377.","journal-title":"Iran J Pharm Res"},{"issue":"4","key":"3782_CR84","first-page":"334","volume":"23","author":"SG Mortazavi Moghadam","year":"2016","unstructured":"Mortazavi Moghadam SG, et al. Effect of Atorvastatin on blood and gasometrical parameters in patients with COPD: a double-blind controlled clinical trial: short communication. J Birjand Univ Med Sci. 2016;23(4):334\u201341.","journal-title":"J Birjand Univ Med Sci"},{"issue":"8","key":"3782_CR85","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s11095-022-03201-5","volume":"39","author":"P Chan","year":"2022","unstructured":"Chan P, Peskov K, Song X. Applications of model-based meta-analysis in drug development. Pharm Res. 2022;39(8):1761\u201377.","journal-title":"Pharm Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03782-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:03:13Z","timestamp":1769076193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3782"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03782-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Nephrology and Urology Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, the Islamic Republic of Iran, approval number [IR.BMSU.BAQ.REC.1404.002].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}